Text Size
29 studies found for:    regorafenib

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Not yet recruiting Pharmacokinetics and Safety of Regorafenib (BAY73-4506) in Cancer Subjects With Severe Renal Impairment
Condition: Neoplasms
Intervention: Drug: Regorafenib (Stivarga, BAY73-4506)
2 Not yet recruiting Regorafenib Post-marketing Surveillance
Condition: Colorectal Neoplasms
Intervention: Drug: BAY73-4506_Regorafenib
3 Completed Effect of Ketoconazole on Regorafenib (BAY73-4506) Pharmacokinetics
Condition: Pharmacokinetics
Intervention: Drug: Regorafenib (BAY73-4506); Regorafenib (BAY73-4506) plus ketoconazole
4 Recruiting Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer
Condition: Colorectal Cancer Metastatic
Interventions: Drug: Regorafenib (BAY 73-4506);   Drug: FOLFIRI;   Drug: Placebo
5 Completed Determination of Safety, Efficacy, and Pharmacokinetics of "Regorafenib" Combined With Pemetrexed and Cisplatin in Patients With Nonsquamous Non-Small Cell Lung Cancer
Condition: Small Cell Lung Carcinoma
Interventions: Drug: Regorafenib (BAY73-4506) - sequential / Cisplatin / Pemetrexed;   Drug: Regorafenib (BAY73-4506) - continuous / Cisplatin / Pemetrexed
6 Completed The Effect of Food (High Fat and Low Fat Breakfast) on the Pharmacokinetics of Regorafenib
Conditions: Dietary Fats;   Pharmacokinetics
Intervention: Drug: Regorafenib (Stivarga, BAY73-4506)
7 Not yet recruiting Regorafenib in Subjects With Metastatic Colorectal Cancer (mCRC) Who Have Progressed After Standard Therapy
Condition: Colorectal Neoplasms
Intervention: Drug: Regorafenib (BAY73- 4506)
8 Active, not recruiting Open Label Regorafenib Study to Evaluate Cardiovascular Safety Parameters, Tolerability, and Anti-tumor Activity
Condition: Neoplasms
Intervention: Drug: Regorafenib (Stivarga, BAY73-4506)
9 Not yet recruiting Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
Condition: Carcinoma, Hepatocellular
Interventions: Drug: Regorafenib (BAY73-4506);   Drug: Placebo
10 Active, not recruiting First Line Treatment of Metastatic Colorectal Cancer With mFOLFOX6 in Combination With Regorafenib
Condition: Colorectal Neoplasms
Intervention: Drug: Regorafenib (Stivarga, BAY73-4506)
11 Active, not recruiting Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor
Condition: Gastrointestinal Stromal Tumor
Intervention: Drug: regorafenib
12 Completed Phase I Study of BAY73-4506 in Chinese Patients With Advanced, Refractory Solid Tumors
Condition: Neoplasms
Intervention: Drug: Regorafenib (Stivarga, BAY73-4506)
13 Withdrawn Second-line FOLFOX With or Without Regorafenib in mCRC Patients Failed to First-line Irinotecan Plus Fluoropyrimidines
Condition: Metastatic Colorectal Cancer
Interventions: Drug: Regorafenib/FOLFOX;   Drug: Placebo/FOLFOX
14 Active, not recruiting BAY73-4506 Probe Substrate Study
Condition: Neoplasms
Interventions: Drug: Regorafenib (Stivarga, BAY73-4506) + warfarin + omeprazole + midazolam;   Drug: Regorafenib (Stivarga, BAY73-4506) + rosiglitazone
15 Active, not recruiting
Has Results 		Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy
Condition: Metastatic Colorectal Cancer
Interventions: Drug: Regorafenib (Stivarga, BAY73-4506);   Drug: Placebo
16 Active, not recruiting Asian Subjects With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy
Condition: Colorectal Neoplasms
Interventions: Drug: Regorafenib (BAY73-4506);   Drug: Placebo
17 Active, not recruiting
Has Results 		A Phase II Uncontrolled Study of BAY73-4506 in Previously Untreated Patients With Metastatic or Unresectable RCC
Condition: Carcinoma, Renal Cell
Intervention: Drug: Regorafenib (Stivarga, BAY73-4506)
18 Completed WB-DWI for Early Prediction of Therapy Response in Patients With Advanced Metastatic GIST Treated With Regorafenib
Condition: Gastrointestinal Stromal Tumors
Intervention: Procedure: Whole body diffusion MRI
19 Active, not recruiting Continuous Dosing of BAY73-4506 in Patients With Advanced Malignancies
Condition: Neoplasm
Intervention: Drug: Regorafenib (BAY73-4506)
20 Completed Study to Determine Safety, Pharmacokinetics, Pharmacodynamics of BAY73-4506 in Combination With mFOLFOX6 or FOLFIRI
Condition: Colorectal Neoplasms
Intervention: Drug: Regorafenib (BAY73-4506)
To Top

Previous Page Studies Shown (1-20) Next Page (21-29) Show next page of results
† Indicates status has not been verified in more than two years